In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis

Journal of Medical Microbiology
Vincent MathyFabrice Compain

Abstract

The in vitro activity of anti-pseudomonal β-lactams in combination with avibactam was evaluated against 54 multidrug-resistant non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients. Avibactam increased and/or restored the antibacterial activities of ceftazidime and aztreonam against Pseudomonas aeruginosa and Stenotrophomonas maltophilia, respectively. No β-lactam-avibactam combination was active against Achromobacter xylosoxidans.

References

Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·J W MoutonA M Horrevorts
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and In
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Jul 10, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F B SpenckerA C Rodloff
Aug 23, 2005·Respiration; International Review of Thoracic Diseases·Noah LechtzinMichael P Boyle
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Clinical Practice Guidelines for Pulmonary Therapies Committee
Aug 31, 2010·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
Aug 3, 2011·Antimicrobial Agents and Chemotherapy·Julien BadorCatherine Neuwirth
Jul 4, 2012·Proceedings of the National Academy of Sciences of the United States of America·David E EhmannStewart L Fisher
Jan 9, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Valerie WatersFelix Ratjen
May 1, 2013·The Journal of Antimicrobial Chemotherapy·Catherine LlanesUNKNOWN GERPA Study Group
Mar 21, 2015·The European Respiratory Journal·Pierre-Régis BurgelUNKNOWN ERS/ECFS Task Force on Provision of Care for Adults with Cystic Fibrosis in Europe
May 4, 2016·Lancet·J Stuart Elborn
Jul 30, 2017·International Journal of Medical Microbiology : IJMM·S StefaniG Taccetti
Aug 9, 2017·Antimicrobial Agents and Chemotherapy·Maria F MojicaRobert A Bonomo
Feb 7, 2018·International Journal of Antimicrobial Agents·Barbara A SantevecchiShawn H MacVane
Mar 7, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Carlo CastellaniPavel Drevinek

❮ Previous
Next ❯

Citations

Aug 21, 2020·Antimicrobial Agents and Chemotherapy·Burcu IslerDavid L Paterson
Jul 21, 2020·Pharmacotherapy·Hannah K SpencerSamuel L Aitken
May 28, 2021·Clinical Microbiology Reviews·Joanna S Brooke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.